Glenmark to launch a Triple-drug FDC of Teneligliptin + Dapagliflozin + Metformin in India for Type 2 diabetes

Glenmark's Zita portfolio of medicines have been benefiting around 1.75 million Type 2 diabetic patients annually

Akums gets approval for triple combination diabetes treatment

Lilly's phase 2 retatrutide results show the investigational molecule achieved up to 17.5% mean weight reduction

Lilly to further investigate retatrutide for the treatment of obesity in the TRIUMPH phase 3 clinical program

Glenmark launches Triple FDC of Teneligliptin with Pioglitazone and Metformin for adults with Type 2 Diabetes

This FDC has been launched under the brand name Zita-PioMet, and contains Teneligliptin (20 mg) + Pioglitazone (15 mg) + Metformin (500mg/1000mg) in a sustained release (SR) formulation

BeatO appoints Dr. Navneet Agrawal as Chief Clinical Officer

He has published more than 100 research papers in several prestigious national and international journals

Infosys Foundation opens second Diabetes Reversal Counselling Centre in Nagpur

Through lifestyle modifications, ADORE will assess the progress of patients based on parameters like reduction in blood sugar levels and weight, among others

Cadila launches generic sitagliptin versions to treat uncontrolled type 2 diabetes

The two generic drugs have been launched under the brand names Jankey & Sitenali.

Zydus launches Sitaglyn and Siglyn for the management of Type 2 diabetes

The addition of Sitaglyn and Siglyn to our diabetes portfolio will give patients access to a world-class oral therapy to help people manage their diabetes

USFDA approves novel, dual-targeted treatment for type 2 diabetes

In clinical trials, treatment proved more effective than other therapies evaluated

GOQii launches first of its kind one-stop solution for Diabetes care in India

An Integrated programme comprising GOQii device, Glucometer – Contour Plus+1 from Ascensia Diabetes Care India and personalised diabetes coaching